Read the latest
MedTech & Biotech News
Chin Named Chief Financial Officer of Akido
Chin Named Chief Financial Officer of Akido Eric Chin is the new Chief Financial...
Read MoreNeural Chip Detects, Suppresses Neurological Symptoms
<!– Medical Innovation Exchange February 7, 2023 6:40 am Neural Chip Detects, Suppresses Neurological Symptoms
Read MoreAntibacterial Peptide Spray Safe for Use on Wounds
<!– Medical Innovation Exchange February 7, 2023 6:22 am Antibacterial Peptide Spray Safe for Use...
Read MoreTiny Patch for Cardiac Ultrasound Imaging
<!– Medical Innovation Exchange February 7, 2023 6:06 am Tiny Patch for Cardiac Ultrasound Imaging
Read MoreRocket, putting regulatory roadblocks in its rearview, receives show of confidence in gene therapy from FDA
Rocket, putting regulatory roadblocks in its rearview, receives show of confidence in gene therapy from...
Read MoreInvestor Syncona blames bear market's ravaging of British biotechs for ‘disappointing’ returns
Investor Syncona blames bear market's ravaging of British biotechs for ‘disappointing’ returns February 7, 2023...
Read MoreRoche races to regulators after matching AstraZeneca’s rare disease blockbuster in phase 3
Roche races to regulators after matching AstraZeneca’s rare disease blockbuster in phase 3 February 7,...
Read MoreAcute Pulmonary Exacerbations Present Inherent Clinical Challenges, For Now
Acute Pulmonary Exacerbations Present Inherent Clinical Challenges, For Now Pulmonary exacerbation is a serious...
Read MoreDo we need new Alzheimer's scales, or a new perspective on what's meaningful to patients?
Do we need new Alzheimer's scales, or a new perspective on what's meaningful to patients?...
Read MoreCell therapy biotech lays off 25% of staff citing difficult funding environment
Cell therapy biotech lays off 25% of staff citing difficult funding environment February 6, 2023...
Read MoreBMS returns $475M IL-12 oncology asset to Dragonfly’s pond
BMS returns $475M IL-12 oncology asset to Dragonfly’s pond February 6, 2023 6:38 am https://www.fiercebiotech.com/biotech/bms-returns-475m-oncology-asset-back-dragonflys-pond
Read MoreGSK's retrospective trial diversity study shows there's more work to do
GSK's retrospective trial diversity study shows there's more work to do February 6, 2023 5:42...
Read MoreJ&J's latest data for nipocalimab in fetal disorder suggests Momenta acquisition may still pay off
J&J's latest data for nipocalimab in fetal disorder suggests Momenta acquisition may still pay off...
Read MoreBoarding priority review track, Biogen and Sage get August decision date for depression drug approval
Boarding priority review track, Biogen and Sage get August decision date for depression drug approval...
Read MoreEx-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3
Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3 February...
Read MorePop-Up Electrode for Improved Neural Interfaces
<!– Medical Innovation Exchange February 3, 2023 12:06 pm Pop-Up Electrode for Improved Neural Interfaces
Read More4D in unknown dimension as FDA slaps hold on Fabry gene therapy trial
4D in unknown dimension as FDA slaps hold on Fabry gene therapy trial February 3,...
Read MoreBruised by high profile cancer setbacks, Sanofi CEO plots early-stage path ‘back to the magic’
Bruised by high profile cancer setbacks, Sanofi CEO plots early-stage path ‘back to the magic’...
Read MoreDrug discovery biotech Vyant preps to wind down operations, starting with layoffs
Drug discovery biotech Vyant preps to wind down operations, starting with layoffs February 3, 2023...
Read MoreChutes & Ladders—Ginkgo BioWorks CEO to lead federal biotech commission
Chutes & Ladders—Ginkgo BioWorks CEO to lead federal biotech commission February 3, 2023 5:13 am...
Read MoreIs MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with FDA
Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with...
Read MoreSanofi backs down from fight with AstraZeneca, argenx and more by stopping phase 3 trial of $3.7B drug
Sanofi backs down from fight with AstraZeneca, argenx and more by stopping phase 3 trial...
Read MoreGilead puts 3 programs on chopping block, including 2 of 3 indications for IRAK4 inhibitor
Gilead puts 3 programs on chopping block, including 2 of 3 indications for IRAK4 inhibitor...
Read MoreDays after halting leukemia drug, Magenta moves to close its doors
Days after halting leukemia drug, Magenta moves to close its doors February 2, 2023 12:44...
Read MoreBMS knocks down a handful of early cancer candidates amid pipeline cleanout
BMS knocks down a handful of early cancer candidates amid pipeline cleanout February 2, 2023...
Read MoreLilly execs shrug off Alzheimer's rejection while assuring investors safety was not an issue
Lilly execs shrug off Alzheimer's rejection while assuring investors safety was not an issue February...
Read MoreMerck admits defeat in race with Valneva to get first chikungunya vaccine to market
Merck admits defeat in race with Valneva to get first chikungunya vaccine to market February...
Read MorePurple Biotech to paint with Immunorizon's tri-specific antibodies in small M&A deal
Purple Biotech to paint with Immunorizon's tri-specific antibodies in small M&A deal February 2, 2023...
Read MoreInovio hopes Ebola vaccine booster data can provide a shot in the arm
Inovio hopes Ebola vaccine booster data can provide a shot in the arm February 2,...
Read MoreLilly drops 2nd program against NASH target that caught Pfizer's eye
Lilly drops 2nd program against NASH target that caught Pfizer's eye February 2, 2023 4:17...
Read MoreKaruna plunders Goldfinch's nest with hopes of repurposing kidney candidates for neuroscience
Karuna plunders Goldfinch's nest with hopes of repurposing kidney candidates for neuroscience February 2, 2023...
Read MoreThe AKT is over: Roche finally dumps phase 3 prostate cancer prospect
The AKT is over: Roche finally dumps phase 3 prostate cancer prospect February 1, 2023...
Read MoreMesoblast gives allogeneic cell therapy a 2nd try with FDA—but without a new trial
Mesoblast gives allogeneic cell therapy a 2nd try with FDA—but without a new trial February...
Read MoreInnovation, investment in pain and addiction are not meeting the societal burden, report says
Innovation, investment in pain and addiction are not meeting the societal burden, report says February...
Read MoreCleeland Joins Francis Medical Board of Directors
Cleeland Joins Francis Medical Board of Directors Andrew Cleeland, CEO of Fogarty Innovations, has...
Read MoreNovartis hasn’t given up on TIGIT, CEO insists, as Big Pharma ‘active’ in cancer M&A search
Novartis hasn’t given up on TIGIT, CEO insists, as Big Pharma ‘active’ in cancer M&A...
Read MoreEmbattled Evelo hangs on to CEO while letting go of 48 employees after eczema trial misses goals
Embattled Evelo hangs on to CEO while letting go of 48 employees after eczema trial...
Read MoreEmerging from Emergency – Two COVID-Related Developments This Week
Two announcements occurred this week, both of note and connected only by the fact that...
Read More2nd round of layoffs in 2 months for Instil, as cell therapy manufacturing shifts to UK
2nd round of layoffs in 2 months for Instil, as cell therapy manufacturing shifts to...
Read MoreGSK drops celiac program acquired in Sitari buyout—and delivers blow to bid to avert antibiotic apocalypse
GSK drops celiac program acquired in Sitari buyout—and delivers blow to bid to avert antibiotic...
Read MoreNovartis cans branaplam after seeing Huntington’s safety signal, delays orphan drug over slow enrollment
Novartis cans branaplam after seeing Huntington’s safety signal, delays orphan drug over slow enrollment February...
Read MoreThe Turing Test is Dead
The Turing Test is Dead In May 2018, Google showcased a demo of Google...
Read MoreLayoffs continue to batter biotech, with Big Pharmas piling on the pain
Layoffs continue to batter biotech, with Big Pharmas piling on the pain January 31, 2023...
Read MorePfizer CEO says R&D is the 'lifeblood that fuels us,' as spending revs up post-COVID
Pfizer CEO says R&D is the 'lifeblood that fuels us,' as spending revs up post-COVID...
Read MoreDespite blockbuster Altos funding, longevity-focused investment drops by $1B: report
Despite blockbuster Altos funding, longevity-focused investment drops by $1B: report January 31, 2023 6:40 am...
Read MoreAfter snagging most expensive drug title, uniQure doles out $10M upfront for ALS prospect
After snagging most expensive drug title, uniQure doles out $10M upfront for ALS prospect January...
Read MoreInovio orders 2nd round of layoffs in 6 months after vaccine flops
Inovio orders 2nd round of layoffs in 6 months after vaccine flops January 31, 2023...
Read MorePfizer punts pair of orphan drugs amid rare disease R&D rethink
Pfizer punts pair of orphan drugs amid rare disease R&D rethink January 31, 2023 4:33...
Read MoreGilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program
Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program January 31, 2023...
Read MoreMicroneedle Bandage for Hemostatic Control
<!– Medical Innovation Exchange January 30, 2023 10:49 pm Microneedle Bandage for Hemostatic Control
Read MoreFlexible Sensors Detect Heavy Metals in Sweat
<!– Medical Innovation Exchange January 30, 2023 10:43 pm Flexible Sensors Detect Heavy Metals in...
Read MoreQuince lays off 47% of staff, stakes sale sign for asset days after separate pipeline deal
Quince lays off 47% of staff, stakes sale sign for asset days after separate pipeline...
Read MoreFDA Issues Final Guidance on Surveying, Leveling, and Alignment Laser Products
FDA Issues Final Guidance on Surveying, Leveling, and Alignment Laser Products On January 30,...
Read MoreModerna’s RSV shot nabs FDA breakthrough tag, joining Pfizer, GSK in race to approval
Moderna’s RSV shot nabs FDA breakthrough tag, joining Pfizer, GSK in race to approval January...
Read MoreStructure finalizes $111M IPO while cancer-focused Intensity reveals Nasdaq ambitions
Structure finalizes $111M IPO while cancer-focused Intensity reveals Nasdaq ambitions January 30, 2023 5:57 am...
Read MoreAfter 'half-baked' data drop, CureVac releases results on mRNA flu, COVID-19 vaccines in older adults
After 'half-baked' data drop, CureVac releases results on mRNA flu, COVID-19 vaccines in older adults...
Read MoreUltrasound Tornado Rapidly Disrupts Blood Clots
<!– Medical Innovation Exchange January 30, 2023 12:31 am Ultrasound Tornado Rapidly Disrupts Blood Clots
Read MoreNanopore Sensor to Study Protein Aggregation in Neurodegeneration
<!– Medical Innovation Exchange January 30, 2023 12:24 am Nanopore Sensor to Study Protein Aggregation...
Read MoreSmart Walking Stick for Visually Impaired People
<!– Medical Innovation Exchange January 30, 2023 12:13 am Smart Walking Stick for Visually Impaired...
Read MoreHow Real-World Evidence Helps Medical Device Manufacturers Drive Value
How Real-World Evidence Helps Medical Device Manufacturers Drive Value Real-world evidence (RWE) captured during...
Read MoreBiotech pipeline hosts 163 potential meds for mental illness, with depression dominating: PhRMA
Biotech pipeline hosts 163 potential meds for mental illness, with depression dominating: PhRMA January 27,...
Read MoreNeither ear nor there: Altamira stakes for-sale sign again after asset deal crumbles
Neither ear nor there: Altamira stakes for-sale sign again after asset deal crumbles January 27,...
Read MoreGoldfinch Bio falls from the sky after failing to find a path forward for kidney treatments
Goldfinch Bio falls from the sky after failing to find a path forward for kidney...
Read MoreQuince's former leadership returns to scoop up unwanted Alzheimer's assets
Quince's former leadership returns to scoop up unwanted Alzheimer's assets January 27, 2023 6:02 am...
Read MoreSenti slams brakes on CAR-NK program to eke out remaining cash
Senti slams brakes on CAR-NK program to eke out remaining cash January 27, 2023 4:50...
Read MoreCelularity warns 'substantial portion' of staff about possible layoffs after reviewing cell therapy strategy
Celularity warns 'substantial portion' of staff about possible layoffs after reviewing cell therapy strategy January...
Read MoreUK biotech IPOs fell to lowest level for a decade in 2022, but VC funds may offer salvation: report
UK biotech IPOs fell to lowest level for a decade in 2022, but VC funds...
Read MoreChutes & Ladders—Johnson & Johnson CMO Joanne Waldstreicher announces retirement
Chutes & Ladders—Johnson & Johnson CMO Joanne Waldstreicher announces retirement January 26, 2023 11:33 am...
Read MoreXyloCor gene therapy hits goals, paving way for phase 3 in cardiovascular space with no current treatment
XyloCor gene therapy hits goals, paving way for phase 3 in cardiovascular space with no...
Read More2 deals in 2 weeks: GenKOre signs pacts worth up to $650M biobucks for gene-editing tech
2 deals in 2 weeks: GenKOre signs pacts worth up to $650M biobucks for gene-editing...
Read MoreAs Sesen investors allege a 'bribe' was offered to support planned Carisma merger, company says they’re ‘opportunists’
As Sesen investors allege a 'bribe' was offered to support planned Carisma merger, company says...
Read MoreSanofi dives deeper into phase 3 data for Hemlibra rival as FDA decision approaches
Sanofi dives deeper into phase 3 data for Hemlibra rival as FDA decision approaches January...
Read MoreEarly data from AC Immune Alzheimer's vaccine suggests a response, setting up next phase of study
Early data from AC Immune Alzheimer's vaccine suggests a response, setting up next phase of...
Read MoreWhat They Said – Looking Back at FDA Press Releases During 2022
Each year Eye on FDA provides a look-back to see what the agency was talking...
Read MoreMiss for Aridis as antibody flunks undersized phase 3 pneumonia trial
Miss for Aridis as antibody flunks undersized phase 3 pneumonia trial January 26, 2023 4:27...
Read MoreOcuphire still focused on FDA approval despite diabetic eye drug missing phase 2 endpoint
Ocuphire still focused on FDA approval despite diabetic eye drug missing phase 2 endpoint January...
Read MoreAfter dose de-escalation, death drives Magenta to pause antibody-drug conjugate leukemia trial
After dose de-escalation, death drives Magenta to pause antibody-drug conjugate leukemia trial January 26, 2023...
Read MoreInhibikase, FDA find common ground to lift hold on Parkinson's drug
Inhibikase, FDA find common ground to lift hold on Parkinson's drug January 25, 2023 7:12...
Read MoreCreating a new dimension: Biotech VC merging tech and life sciences unveils with $350M
Creating a new dimension: Biotech VC merging tech and life sciences unveils with $350M January...
Read MoreCidara wins ‘difficult’ AdComm vote, securing near-unanimous support despite antifungal data doubts
Cidara wins ‘difficult’ AdComm vote, securing near-unanimous support despite antifungal data doubts January 25, 2023...
Read MoreConnected Care: Overcoming Roadblocks and Identifying Opportunities
Connected Care: Overcoming Roadblocks and Identifying Opportunities What’s next—and what’s holding us back—on the...
Read MoreKSQ scores 'double-digit million' payment from Japan's Ono for preclinical cancer programs
KSQ scores 'double-digit million' payment from Japan's Ono for preclinical cancer programs January 25, 2023...
Read MoreBristol Myers CMO still skeptical about cancer vaccines as BioNTech, Moderna march ahead with I-O partners
Bristol Myers CMO still skeptical about cancer vaccines as BioNTech, Moderna march ahead with I-O...
Read MoreEMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval
EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval January 25, 2023...
Read MoreTackling Go-To-Market Challenges
Tackling Go-To-Market Challenges The medical device industry is amid an era of unprecedented regulatory...
Read MoreMatt Gline wants you to stop thinking of Roivant as a discard company. In 2023, he'll prove it
Matt Gline wants you to stop thinking of Roivant as a discard company. In 2023,...
Read MoreBehind the deal: AstraZeneca’s eagerness for CinCor acquisition revealed in larger initial offer
Behind the deal: AstraZeneca’s eagerness for CinCor acquisition revealed in larger initial offer January 24,...
Read MoreCassava claims win in open-label Alzheimer's study, but shares decline 15%
Cassava claims win in open-label Alzheimer's study, but shares decline 15% January 24, 2023 7:04...
Read MoreJ&J trims the edges of its pipeline with the company mum on timing of looming readouts
J&J trims the edges of its pipeline with the company mum on timing of looming...
Read MoreFrosty funding forecast forces Finch to stop phase 3 trial, lay off 95% of staff and seek buyers for assets
Frosty funding forecast forces Finch to stop phase 3 trial, lay off 95% of staff...
Read MoreLaw firms target Spectrum over lung cancer trial statements
Law firms target Spectrum over lung cancer trial statements January 24, 2023 3:38 am https://www.fiercebiotech.com/biotech/law-firms-target-spectrum-over-disclosure-lung-cancer-data
Read MoreThe rise of venture debt and when biotechs should—and shouldn't—use it
The rise of venture debt and when biotechs should—and shouldn't—use it January 23, 2023 1:08...
Read MoreCombo results may offer route back to approval for Agenus' unlucky cervical cancer drug
Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug January...
Read MoreMerck KGaA shrinks U.S. research team as layoffs continue to batter industry
Merck KGaA shrinks U.S. research team as layoffs continue to batter industry January 23, 2023...
Read MoreMorphic loses another Big Pharma partner as J&J follows AbbVie out of the door
Morphic loses another Big Pharma partner as J&J follows AbbVie out of the door January...
Read MoreChasing Boehringer, Pliant sends stock soaring with midphase fibrosis data
Chasing Boehringer, Pliant sends stock soaring with midphase fibrosis data January 23, 2023 2:08 am...
Read MoreInstilling Trust in AI
Instilling Trust in AI Artificial intelligence (AI) has become one of the most exciting...
Read MoreFDA Seeks Input on Advancing Use of Real-World Data and Evidence
FDA Seeks Input on Advancing Use of Real-World Data and Evidence The FDA is...
Read MoreBiotech may soon be defined by the 'haves and have-nots' as investors look for less risky bets
Biotech may soon be defined by the 'haves and have-nots' as investors look for less...
Read MoreBalance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance
<!– Medical Innovation Exchange January 20, 2023 8:06 am Balance Boards to Stay Active in...
Read MoreBiobots Use Optogenetic Muscle Actuators for Movement
<!– Medical Innovation Exchange January 20, 2023 7:54 am Biobots Use Optogenetic Muscle Actuators for...
Read MoreEyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug
Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug January 20, 2023 5:13...
Read MoreDisc spins faster by paying Mabwell $10M for clinic-ready blood disorder candidate
Disc spins faster by paying Mabwell $10M for clinic-ready blood disorder candidate January 20, 2023...
Read MoreAstellas, after years of gene therapy woes, gets rare boost with FDA lifting of Pompe clinical hold
Astellas, after years of gene therapy woes, gets rare boost with FDA lifting of Pompe...
Read MoreCyteir lays off 70% of workforce after further narrowing cancer drug goals
Cyteir lays off 70% of workforce after further narrowing cancer drug goals January 20, 2023...
Read MoreEli Lilly shut out of Alzheimer’s fast lane with FDA rejection for donanemab
Eli Lilly shut out of Alzheimer’s fast lane with FDA rejection for donanemab January 19,...
Read MoreChutes & Ladders—David Kessler resigns from the Biden admin, marking the unofficial end of Operation Warp Speed
Chutes & Ladders—David Kessler resigns from the Biden admin, marking the unofficial end of Operation...
Read MoreArtificial Neuron Uses Ions Like the Real Thing
<!– Medical Innovation Exchange January 19, 2023 11:09 am Artificial Neuron Uses Ions Like the...
Read MoreConcert joins Sun Pharma’s symphony for $576M with aim of bringing alopecia treatment to market
Concert joins Sun Pharma’s symphony for $576M with aim of bringing alopecia treatment to market...
Read MoreJiving with Jazz after $325M opt-in, Zymeworks links HER2 bispecific to 84% survival after 18 months
Jiving with Jazz after $325M opt-in, Zymeworks links HER2 bispecific to 84% survival after 18...
Read MoreEditas finds buyer for iNK programs 10 days after clearing out pipeline
Editas finds buyer for iNK programs 10 days after clearing out pipeline January 19, 2023...
Read MoreReNeuron lays off 40% of staff after funding failure, buying time to execute exosome pivot
ReNeuron lays off 40% of staff after funding failure, buying time to execute exosome pivot...
Read MoreMineralys polishes $100M IPO plans ahead of phase 3 in hypertension
Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension January 19, 2023 2:17...
Read MoreFDA To Host Webinar on Electromagnetic Compatibility of In Vitro Diagnostic Devices
FDA To Host Webinar on Electromagnetic Compatibility of In Vitro Diagnostic Devices The FDA...
Read MoreGilead fosters growth with plans for new research center in California hometown
Gilead fosters growth with plans for new research center in California hometown January 18, 2023...
Read MoreSPAC to it: Alzheimer’s-focused Aprinoia inks deal with Wilbur Ross' blank check company
SPAC to it: Alzheimer’s-focused Aprinoia inks deal with Wilbur Ross' blank check company January 18,...
Read MoreJ&J packs up HIV vaccine after failing phase 3 trial
J&J packs up HIV vaccine after failing phase 3 trial January 18, 2023 6:24 am...
Read MoreIrlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial
Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial January 18, 2023...
Read MoreHydrogel Scaffold Makes a Living Electrode
<!– Medical Innovation Exchange January 18, 2023 5:54 am Hydrogel Scaffold Makes a Living Electrode
Read MoreHorizon, on victory lap before Amgen buyout, racks up 2nd win in Sjögren's to claim unique double
Horizon, on victory lap before Amgen buyout, racks up 2nd win in Sjögren's to claim...
Read MorePhase 2 attrition jumps amid widespread scale-back in overall clinical trial activity: study
Phase 2 attrition jumps amid widespread scale-back in overall clinical trial activity: study January 18,...
Read MoreIntricon Launches Biosensors Center of Excellence
Intricon Launches Biosensors Center of Excellence Intricon, a developer and manufacturer of medical devices...
Read MoreHow 2 biotechs survived 2022’s rocky market—and why their CEOs see success on the horizon
How 2 biotechs survived 2022’s rocky market—and why their CEOs see success on the horizon...
Read MoreSustainability: Lessons from the Frontlines of Health Care
Sustainability: Lessons from the Frontlines of Health Care Healthcare leaders today face the complicated...
Read MorePlaying catch-up to Big Pharma, Moderna posts come-from-behind RSV data
Playing catch-up to Big Pharma, Moderna posts come-from-behind RSV data January 17, 2023 11:09 am...
Read MoreA trio of biotechs consolidate as M&A fails to materialize at JPM
A trio of biotechs consolidate as M&A fails to materialize at JPM January 17, 2023...
Read MoreNewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2, opening new front in race to market
NewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2, opening new front in race to...
Read MoreElicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move
Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move...
Read MoreFirst hiccup for Basilea's anti-infective strategy as biotech hands back antifungal 9 months after licensing it
First hiccup for Basilea's anti-infective strategy as biotech hands back antifungal 9 months after licensing...
Read MoreAbionyx hails success of bid to resurrect failed cholesterol drug—without dishing data to back up claims
Abionyx hails success of bid to resurrect failed cholesterol drug—without dishing data to back up...
Read MoreWhen the Going Gets Tough – FDA AdComms in 2022
Through its Human Drugs Advisory Committee process FDA has a vast array of outside experts...
Read MoreTCR² removed 20% of staff over summer, paving way for latest layoffs
TCR² removed 20% of staff over summer, paving way for latest layoffs January 13, 2023...
Read MoreChutes & Ladders—Novavax CEO Erck bids adieu after 12 years, overseeing COVID vax development
Chutes & Ladders—Novavax CEO Erck bids adieu after 12 years, overseeing COVID vax development January...
Read MoreUsing real RWD to better understand and engage neuro patients
Using real RWD to better understand and engage neuro patients January 12, 2023 9:42 am...
Read MoreSanofi pumps $750M into VC unit to push deeper into biotech investing
Sanofi pumps $750M into VC unit to push deeper into biotech investing January 12, 2023...
Read MoreJPM23: After hiatus, Teva looks to amp up research collaborations, CEO says
JPM23: After hiatus, Teva looks to amp up research collaborations, CEO says January 12, 2023...
Read MoreGSK grabs 150K square feet of prime Boston lab space as part of RNA, viral focus
GSK grabs 150K square feet of prime Boston lab space as part of RNA, viral...
Read MoreOramed’s oral insulin flunks phase 3 diabetes test, sending stock down 70%
Oramed’s oral insulin flunks phase 3 diabetes test, sending stock down 70% January 12, 2023...
Read MoreJPM23: After rock climbing in biotech, Novartis’ CMO is back to support hopeful hike to US summit
JPM23: After rock climbing in biotech, Novartis’ CMO is back to support hopeful hike to...
Read MoreJPM23: Nektar pins comeback hopes on Lilly collab and cancer combinator following bempeg blowup
JPM23: Nektar pins comeback hopes on Lilly collab and cancer combinator following bempeg blowup January...
Read MoreEnhancing Clinical Trials with More Diverse Recruitment
Enhancing Clinical Trials with More Diverse Recruitment January 11, 2023 11:21 am https://www.fiercebiotech.com/sponsored/deconstructing-what-causes-clinical-trials-fall-short
Read MoreJPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed
JPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed January 11,...
Read MoreJPM23: Annexon looks for 'two ways to win' in upcoming Huntington's trial
JPM23: Annexon looks for 'two ways to win' in upcoming Huntington's trial January 11, 2023...
Read More4D's Fabry gene therapy flounders amid adverse events, further weakening Sangamo's competition
4D's Fabry gene therapy flounders amid adverse events, further weakening Sangamo's competition January 11, 2023...
Read MoreBioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop...
Read MoreEuropean Commission Proposes Extended Timeline for EU MDR/IVDR Compliance
European Commission Proposes Extended Timeline for EU MDR/IVDR Compliance On January 6, the...
Read MoreJPM23: Editas touts skinnier pipeline after major shake-up to ride out 'unfriendly' markets
JPM23: Editas touts skinnier pipeline after major shake-up to ride out 'unfriendly' markets January 11,...
Read MoreJPM23, Day 3: Takeda relishing in-person meetups
JPM23, Day 3: Takeda relishing in-person meetups January 11, 2023 12:56 am https://www.fiercebiotech.com/biotech/jpm23-day-3-takeda-relishing-person-meet-ups
Read MoreBest Practices and Pitfalls When Going from Concept to Commercialization
Best Practices and Pitfalls When Going from Concept to Commercialization MedTech Internet of things...
Read MoreJPM23: BioNTech not giving up on fighting symptomatic COVID as oncology ambitions spread
JPM23: BioNTech not giving up on fighting symptomatic COVID as oncology ambitions spread January 10,...
Read MoreJPM23: Sage CEO says postpartum depression is no niche, as zuranolone aims to fill gaps in mental healthcare
JPM23: Sage CEO says postpartum depression is no niche, as zuranolone aims to fill gaps...
Read MoreJPM23: Karuna CEO says biotech can launch drugs too, as deal rumors circulate
JPM23: Karuna CEO says biotech can launch drugs too, as deal rumors circulate January 10,...
Read MoreKing Joins KMM Group as Healthcare Industry Advisor
King Joins KMM Group as Healthcare Industry Advisor J. Mark King, a long-time healthcare...
Read MoreJPM23: Roivant CEO says 2023 shaping up to be 'single most exciting year' for new readouts
JPM23: Roivant CEO says 2023 shaping up to be 'single most exciting year' for new...
Read MoreJasper pulls out of pivotal blood cancer trial at the last minute to prioritize other indications
Jasper pulls out of pivotal blood cancer trial at the last minute to prioritize other...
Read MoreAlto’s hopes for brain biomarker strategy rise on phase 2 antidepressant data
Alto’s hopes for brain biomarker strategy rise on phase 2 antidepressant data January 10, 2023...
Read MoreAbbVie, following in footsteps of Lilly and Takeda, pays Anima $42M to go after undruggable targets
AbbVie, following in footsteps of Lilly and Takeda, pays Anima $42M to go after undruggable...
Read MoreJPM23, Day 2: VCs still have cash to fund biotech, says investor
JPM23, Day 2: VCs still have cash to fund biotech, says investor January 10, 2023...
Read MoreCash-strapped Calithera closes down in shadow of enrollment delays to cancer trials
Cash-strapped Calithera closes down in shadow of enrollment delays to cancer trials January 10, 2023...
Read MoreNew Cybersecurity Standards for Medical Applications
New Cybersecurity Standards for Medical Applications An increasing number of pacemakers, insulin pumps and...
Read MoreJPM23: Beam hopes to sidestep sickle cell peers with next-gen gene editing
JPM23: Beam hopes to sidestep sickle cell peers with next-gen gene editing January 9, 2023...
Read MoreJPM23: Lilly has a full plate, as CMO jokes, 'we need to leave J.P. Morgan and get back to work'
JPM23: Lilly has a full plate, as CMO jokes, 'we need to leave J.P. Morgan...
Read MoreJPM23: Mirati's post-Krazati pipeline restock to focus on 'highest opportunity for capital'
JPM23: Mirati's post-Krazati pipeline restock to focus on 'highest opportunity for capital' January 9, 2023...
Read MoreAnnexon, Liminal shrink pipelines to prioritize potential homerun candidates
Annexon, Liminal shrink pipelines to prioritize potential homerun candidates January 9, 2023 6:56 am https://www.fiercebiotech.com/biotech/annexon-liminal-shrink-pipelines-prioritize-potential-homerun-candidates
Read MoreGood day for Day One as pediatric brain tumor drug proves worth in phase 2
Good day for Day One as pediatric brain tumor drug proves worth in phase 2...
Read MoreTakeda, Arrowhead hit one target for rare disease drug, but placebo overperformance sends biotech's shares tumbling
Takeda, Arrowhead hit one target for rare disease drug, but placebo overperformance sends biotech's shares...
Read MoreBoehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform
Boehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform January...
Read MorePharvaris to embark on 6-month tox test in hopes of reversing US clinical hold for HAE asset
Pharvaris to embark on 6-month tox test in hopes of reversing US clinical hold for...
Read MoreNovavax CEO Stanley Erck retires after overseeing COVID shot launch
Novavax CEO Stanley Erck retires after overseeing COVID shot launch January 9, 2023 5:36 am...
Read MoreAstellas continues intergalactic licensing quest, signing onto 2 new pacts
Astellas continues intergalactic licensing quest, signing onto 2 new pacts January 9, 2023 5:29 am...
Read MoreEditas rewrites its own code after tough 2022, sending staff packing and editing down programs
Editas rewrites its own code after tough 2022, sending staff packing and editing down programs...
Read MoreNeurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab
Neurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab January...
Read MoreLilly rides TRex into regulatory T-cell space, paying $55M upfront for 3 immune-mediated disease drugs
Lilly rides TRex into regulatory T-cell space, paying $55M upfront for 3 immune-mediated disease drugs...
Read MoreStalicla pledges $270M to take forward Novartis’ failed former fragile X candidate
Stalicla pledges $270M to take forward Novartis’ failed former fragile X candidate January 9, 2023...
Read MoreCapitalizing on share price crash, AstraZeneca inks $1.8B CinCor takeover for blood pressure drug
Capitalizing on share price crash, AstraZeneca inks $1.8B CinCor takeover for blood pressure drug January...
Read MoreJPM23, Day 1: AstraZeneca scoops CinCor for cardiorenal drug; Genentech seals small molecule pact
JPM23, Day 1: AstraZeneca scoops CinCor for cardiorenal drug; Genentech seals small molecule pact January...
Read MoreRoche offers up to $554M in biobucks to in-need Kronos for small molecule discovery pact
Roche offers up to $554M in biobucks to in-need Kronos for small molecule discovery pact...
Read MoreFlagship Pioneering CEO urges shareholders to stay the course on 'choppy' biotech markets: 'See you on the seas'
Flagship Pioneering CEO urges shareholders to stay the course on 'choppy' biotech markets: 'See you...
Read MoreFierce Biotech Layoff Tracker 2023: Editas edits down workforce, plus more
Fierce Biotech Layoff Tracker 2023: Editas edits down workforce, plus more January 6, 2023 11:49...
Read MoreKaruna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch January...
Read MoreBioprinted Eye Tissue to Study Retinal Diseases
<!– Medical Innovation Exchange January 6, 2023 7:45 am Bioprinted Eye Tissue to Study Retinal...
Read MoreBioNTech signs UK government pact to deliver cancer therapies to 100k patients by 2023
BioNTech signs UK government pact to deliver cancer therapies to 100k patients by 2023 January...
Read MoreAbbVie inks $1.3B biobucks deal with Immonome in hopes of developing antibody therapeutics for solid tumors
AbbVie inks $1.3B biobucks deal with Immonome in hopes of developing antibody therapeutics for solid...
Read MoreCureVac's 'half-baked' COVID-flu data release questioned by analysts, but shares still rally 17%
CureVac's 'half-baked' COVID-flu data release questioned by analysts, but shares still rally 17% January 6,...
Read MoreCentury, Elevation are latest to follow layoff, pipeline cull route as Nabriva winds down
Century, Elevation are latest to follow layoff, pipeline cull route as Nabriva winds down January...
Read MoreModerna caps off busy week with $1.2B CytomX collab to better target mRNA therapies
Moderna caps off busy week with $1.2B CytomX collab to better target mRNA therapies January...
Read MorePfizer pivots from early-stage rare disease R&D, shifting to external innovation and putting assets up for sale
Pfizer pivots from early-stage rare disease R&D, shifting to external innovation and putting assets up...
Read MoreFate hits reset as J&J cell therapy deal collapses, slashing pipeline and head count to stretch cash
Fate hits reset as J&J cell therapy deal collapses, slashing pipeline and head count to...
Read MoreGraphite's hopes for sickle cell 'cure' blunted after first patient dosed experiences serious event
Graphite's hopes for sickle cell 'cure' blunted after first patient dosed experiences serious event January...
Read MoreChutes & Ladders—2 more C-suite members leave Galapagos island
Chutes & Ladders—2 more C-suite members leave Galapagos island January 5, 2023 3:22 pm https://www.fiercebiotech.com/biotech/chutes-ladders-galapagos-sees-two-more-c-suite-members-leave-island
Read MorePoint-Of-Care Biosensor to Detect Oral Cancer
<!– Medical Innovation Exchange January 5, 2023 9:52 am Point-Of-Care Biosensor to Detect Oral Cancer
Read MoreOptogenetics Tech for Long-Term Changes in Neuronal Excitability
<!– Medical Innovation Exchange January 5, 2023 9:22 am Optogenetics Tech for Long-Term Changes in...
Read MoreRoche further taps drug discovery spinout's Nimble tech in $1.1B biobucks deal
Roche further taps drug discovery spinout's Nimble tech in $1.1B biobucks deal January 5, 2023...
Read MoreRenibus’ cardiac surgery drug aces phase 2 trial as biotech adds extra CEO
Renibus’ cardiac surgery drug aces phase 2 trial as biotech adds extra CEO January 5,...
Read MoreAmgen piles $2B more into pharma's ADC rush in Synaffix pact
Amgen piles $2B more into pharma's ADC rush in Synaffix pact January 5, 2023 5:48...
Read MoreTakeda troops rare disease drug to regulators after glimpse at phase 3 data
Takeda troops rare disease drug to regulators after glimpse at phase 3 data January 5,...
Read MoreBurned by FDA rejection, Y-mAbs drops 3rd of staff, cancer vaccine ambitions
Burned by FDA rejection, Y-mAbs drops 3rd of staff, cancer vaccine ambitions January 5, 2023...
Read MoreGSK pays WuXi $40M, bets $1.5B in biobucks for preclinical anti-cancer bispecific antibodies
GSK pays WuXi $40M, bets $1.5B in biobucks for preclinical anti-cancer bispecific antibodies January 5,...
Read MoreBiopharmas left Black and Latinx patients behind in oncology clinical trials, nonprofit says
Biopharmas left Black and Latinx patients behind in oncology clinical trials, nonprofit says January 4,...
Read MoreEisai rebuts NEJM report that Alzheimer's med contributed to patient's stroke death
Eisai rebuts NEJM report that Alzheimer's med contributed to patient's stroke death January 4, 2023...
Read More